O
2.53
0.10 (4.24%)
| Previous Close | 2.43 |
| Open | 2.45 |
| Volume | 13,074 |
| Avg. Volume (3M) | 686,777 |
| Market Cap | 21,044,158 |
| Price / Sales | 0.130 |
| Price / Book | 0.080 |
| 52 Weeks Range | |
| Earnings Date | 20 May 2024 |
| Operating Margin (TTM) | -300.33% |
| Diluted EPS (TTM) | -87.25 |
| Current Ratio (MRQ) | 0.100 |
| Operating Cash Flow (TTM) | -15.78 M |
| Levered Free Cash Flow (TTM) | -6.06 M |
| Return on Assets (TTM) | -21.85% |
| Return on Equity (TTM) | -1,758.48% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Onconetix, Inc. | - | - |
AIStockmoo Score
0.0
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 57.93% |
| % Held by Institutions | 7.86% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |